Resapp Health Ltd traded at 0.13 this Thursday July 7th, decreasing 0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Resapp Health Ltd lost 21.21 percent. Over the last 12 months, its price rose by 195.45 percent. Looking ahead, we forecast Resapp Health Ltd to be priced at 0.13 by the end of this quarter and at 0.12 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.13
Daily Change
0%
Yearly
195.45%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alcidion Group Ltd 0.13 -0.01 -3.85% -65.75%
Fisher & Paykel Healthcare 19.27 0.14 0.73% -31.67%
PainChek Ltd 0.03 0.001 3.13% -46.77%
Pro Medicus Ltd 45.19 -0.03 -0.07% -21.11%
ResMed 32.14 -0.36 -1.11% -4.09%
Volpara Health Technologies Ltd 0.54 0.01 0.93% -53.85%


Resapp Health Ltd
ResApp Health Limited is an Australia-based company, which is engaged in developing digital healthcare solutions. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The Company has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The Company has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. It also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The Company has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.